Resources
Blog Posts
Koneksa is at the forefront of digital biomarker discovery and testing, and our science-based understanding of their capabilities across therapeutic areas gives us a unique perspective. We are proud to share our insights, and we welcome your inquiries. Explore our articles to gain insights into the potential of digital biomarkers in clinical research.
Found 59 Results
Page 3 of 10
Article
7th Annual Digital Biomarkers in Clinical Trials Summit
We were privileged to attend the 7th Annual Digital Biomarkers in Clinical Trials Summit at the Roche Headquarters in Basel on June 26th, 2024. Over 300 attendees attended the consortium,... Download
Article
Moving Drug Development Forward Through a Focus on Clinical Outcome Assessments: Koneksa at Recent Critical-Path Institute Meetings
Last week, two important events happened, both hosted by the Critical Path Institute (C-Path): the Electronic Clinical Outcome Assessment (eCOA) Consortium meeting on April 16, and the 2024 Clinical Outcome... Download
Article
Patients As Partners, Not Passengers: Thoughts from the ASCPT 2024 Patient Forum
The American Society for Clinical Pharmacology & Therapeutics(ASCPT) hosted a Patient Forum on March 28 at the 2024 annual meeting. I was privileged to chair the discussion, which centered on... Download
Article
The Critical Gap Has Been Addressed: Mobilise-D Shares the Results of Its 7-Year Journey
The Mobilise-D Consortium gathered in Edinburgh, Scotland on March 20, 2024 for an end-of-project conference, which turned into a day of celebration of science. The idea of putting together efforts... Download
Article
Koneksa’s Usability Testing Case Study: Alignment with DiMe’s V3+ Framework
Koneksa contributed to the new Digital Medicine Society (DiMe) V3+ framework, which adds usability to the process of validating digital health technologies (DHTs). Usability is an important aspect of successful…
DownloadArticle
How Parkinson’s disease research is changing, and needs to: Notes from ADPD
The recent Alzheimer’s and Parkinson’s Disease Conference (ADPD) demonstrated that it is an exciting time for drug development in Parkinson’s disease. Parkinson’s disease is being redefined by alpha synuclein biology,…
Download
